Prognostic Model of HCV-related Disease Progression After DAAs
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 234
- 主要终点
- incidence of composit liver-related events
研究概览
简要总结
In this study, the investigator would conduct an ambispective cohort study to build a prediction model of HCV-related disease after DAAs.
详细描述
The emergence of direct antiviral agents (DAAs) makes it possible to cure HCV, and the sustained virological response (SVR) rate is up to 90% after DAAs therapy. However, the acquisition of SVR does not mean the cure of HCV-related diseases, some patients still developed liver cirrhosis, liver cancer and other diseases after achived SVR by DAAs therapy.In this study the investigator would like to bulid a prediction model of HCV-related disease after DAAs by conducting an ambispective cohort study. The participants of this study would be adult patients (≥18 years old) with chronic HCV infection and have received DAA therapy, the investigator would retrospectively collected DAA therapy-related information, and follow-up all the enrolled participants every 6 months to observe their liver-related disease outcomes (composite liver outcome, including liver-related deaths, hepatocellular carcinoma, liver decompensation, and liver transplantation).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adult patients (≥18 years old) with chronic HCV infection that were HCV RNA positive;
- •have received DAA treatment;
- •would like to adhere to the follow-up
排除标准
- •lack of HCV treatment information;
结局指标
主要结局
incidence of composit liver-related events
时间窗: through study completion, an average of 2 year
Composite liver outcomes, including liver-related deaths, hepatocellular carcinoma, liver decompensation, or liver transplantation.
次要结局
未报告次要终点
研究者
Liu Huixin
Assistant professor
Peking University People's Hospital